SIBIA Neurosciences (SIBI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (368)	5/26/1999 10:45:00 PM
From: scaram(o)uche	Read Replies (2) of 579

Mike: What do you think the royalty is that is associated with the option? If it's 20% and (1) Lilly pays for all clinical development if they exercise the option, and (2) SIBI feels great because they now have the resources to develop the VGCC/pain program, what will you think? These were small, phase II projects. I don't expect to have a $50/share company overnight, so I'll wait to see what the terms are. They were going to license, that was clear. Now, they have given an option. I consider that to be quite clever, if the proposed revenue streams are reasonably divided. We'll see how it turns out. I'm surprised by the intense negative sentiment. I walked away from today's session as a happy camper, even with the weak close. Good luck, all! Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next